Herpes Marker Testing
Description
Global Herpes Marker Testing Market to Reach US$731.1 Million by 2032
The global market for Herpes Marker Testing estimated at US$527.0 Million in the year 2025, is expected to reach US$731.1 Million by 2032, growing at a CAGR of 4.8% over the analysis period 2025-2032. Viral Culture Test Kits Test, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$305.4 Million by the end of the analysis period. Growth in the Nucleic Acid Amplification-based Kits Test segment is estimated at 5.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$163.0 Million While China is Forecast to Grow at 8.7% CAGR
The Herpes Marker Testing market in the U.S. is estimated at US$163.0 Million in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$180.7 Million by the year 2032 trailing a CAGR of 8.7% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.
Global Herpes Marker Testing Market - Key Trends and Drivers Summarized
Is Herpes Marker Testing the Key to Effective Management of Viral Infections?
Herpes marker testing plays a critical role in diagnosing and managing herpes simplex virus (HSV) infections, but why is this testing so essential? Herpes marker tests are used to detect the presence of antibodies or viral DNA in the body, helping clinicians identify whether an individual has been infected with HSV-1 or HSV-2, the two most common strains of the virus. HSV-1 is typically associated with oral herpes (cold sores), while HSV-2 is more commonly linked to genital herpes, although both types can infect either region. Herpes infections are widespread, with millions of people worldwide living with either type of the virus, many of whom are unaware they are carriers due to the often asymptomatic nature of the infection.
Herpes marker testing is critical for diagnosing the virus, particularly in asymptomatic individuals or those with mild symptoms, as they can unknowingly transmit the virus to others. Testing for herpes involves identifying specific antibodies (IgG or IgM) that the immune system produces in response to the infection or detecting viral DNA through polymerase chain reaction (PCR) tests. These tests help confirm whether someone has been exposed to the virus and, in many cases, can indicate whether the infection is recent or long-standing. Accurate diagnosis through herpes marker testing is essential for managing outbreaks, reducing the risk of transmission, and guiding treatment options to help individuals manage symptoms and prevent complications.
How Has Technology Advanced Herpes Marker Testing?
Technological advancements have significantly improved herpes marker testing, making it more accurate, faster, and accessible. One of the most significant innovations in this field is the development of polymerase chain reaction (PCR) testing, which allows for the direct detection of viral DNA. PCR testing is highly sensitive and can detect even small amounts of the virus in various sample types, such as blood, saliva, or lesion swabs. This method offers rapid and precise results, often within a few hours, making it one of the most reliable diagnostic tools for detecting active herpes infections. PCR tests have become the gold standard for diagnosing HSV infections, especially in cases where a definitive diagnosis is needed quickly, such as during an acute outbreak.
Serological testing, which identifies the presence of antibodies against HSV, has also improved. Traditional blood tests could sometimes struggle to differentiate between HSV-1 and HSV-2 infections. However, modern serological tests now offer type-specific antibody detection, allowing clinicians to distinguish between the two types of the virus. This distinction is crucial because HSV-1 and HSV-2 have different transmission patterns and recurrence rates, which can influence how a patient manages their infection. Type-specific IgG antibody tests can indicate whether someone has had a past infection, while IgM tests help identify recent or primary infections.
Additionally, point-of-care (POC) testing for herpes is becoming increasingly available. These rapid tests offer on-the-spot results, making them useful in urgent care or sexual health clinics where quick diagnosis is critical. Newer technologies are also exploring multiplex testing, which allows for the simultaneous detection of multiple sexually transmitted infections (STIs) alongside HSV, improving efficiency and reducing the number of tests needed to diagnose co-infections. These advancements in herpes marker testing not only improve diagnostic accuracy but also speed up the process, enabling earlier intervention and better management of herpes infections.
Why Is Herpes Marker Testing Critical for Public Health and Personal Management?
Herpes marker testing is vital for public health and personal management because it enables individuals and healthcare providers to detect and control the spread of herpes simplex virus infections, particularly when symptoms are mild or absent. Many people with herpes are unaware of their infection because it can remain dormant in the body for long periods, only causing outbreaks when triggered by factors like stress, illness, or a weakened immune system. Without proper testing, these individuals may unknowingly transmit the virus to others, contributing to its spread. Testing for herpes markers helps identify carriers and allows them to take precautions, such as using antiviral medications or practicing safer sexual behaviors, to reduce the risk of transmission.
For individuals, herpes marker testing provides clarity and peace of mind, particularly if they are experiencing unexplained symptoms like genital or oral sores, itching, or discomfort. A confirmed diagnosis allows healthcare providers to develop a tailored management plan, which may include antiviral medications like acyclovir, valacyclovir, or famciclovir to reduce the frequency and severity of outbreaks. Knowing their HSV status also empowers individuals to take preventive steps to avoid passing the virus to sexual partners, especially during asymptomatic shedding when the virus can still be transmitted.
In pregnant women, herpes marker testing is particularly critical. HSV infections, especially when acquired during pregnancy, can pose risks to the baby, leading to neonatal herpes, a serious condition that can cause permanent disability or death if not treated promptly. Identifying herpes infections early allows doctors to take preventive measures, such as prescribing antiviral medications in the late stages of pregnancy or recommending a cesarean delivery if there are active lesions during labor, to reduce the risk of transmitting the virus to the newborn.
On a larger scale, herpes marker testing is crucial for managing the overall public health impact of HSV infections. The virus is one of the most prevalent sexually transmitted infections globally, and widespread testing can help reduce its transmission rate by identifying and treating carriers. Early detection and effective management of herpes infections also help reduce the stigma associated with the virus, which can prevent individuals from seeking testing or treatment. By normalizing testing and offering easy access to diagnostics, public health systems can more effectively manage the spread of HSV, protect vulnerable populations, and improve the quality of life for those living with the virus.
What Factors Are Driving the Growth of the Herpes Marker Testing Market?
The growth of the herpes marker testing market is driven by several key factors, including rising awareness of sexually transmitted infections (STIs), advancements in testing technologies, and the increasing prevalence of herpes simplex virus infections globally. One of the primary drivers is the growing awareness of STIs and the importance of regular screening. Public health campaigns and educational programs are encouraging more people to get tested for herpes and other STIs, particularly as awareness increases about the asymptomatic nature of HSV infections. This shift in public health awareness is leading to higher demand for herpes marker testing in clinics, hospitals, and at-home testing kits.
Technological advancements in diagnostic testing are also contributing to the growth of the herpes marker testing market. The development of more accurate, faster, and cost-effective tests, such as PCR and multiplex testing, is making herpes diagnostics more accessible to healthcare providers and patients. These technologies allow for quicker turnaround times, which is especially important in managing acute outbreaks and preventing transmission. The introduction of point-of-care (POC) tests that deliver rapid results is another factor fueling market expansion, particularly in regions where healthcare infrastructure may be limited or where immediate results are necessary for treatment decisions.
The rising prevalence of herpes infections is another significant factor driving market growth. The World Health Organization (WHO) estimates that more than 3.7 billion people under the age of 50 have HSV-1, and over 490 million people aged 15–49 have HSV-2. As these infections remain widespread and incurable, the demand for effective diagnostic tools to manage and monitor herpes infections continues to grow. The increasing recognition of the health risks associated with undiagnosed or untreated herpes, such as complications during pregnancy and heightened risk of HIV transmission, is prompting more individuals to seek testing.
The growth of at-home testing options is another trend contributing to market expansion. With the rise of telemedicine and digital health platforms, at-home herpes testing kits are becoming more popular, providing a convenient, discreet, and accessible way for individuals to learn their HSV status. These kits allow users to collect a sample at home and send it to a laboratory for analysis, with results delivered confidentially via secure online platforms. The convenience and privacy offered by these services are encouraging more people, particularly younger and tech-savvy populations, to take charge of their sexual health and get tested.
Lastly, increasing healthcare initiatives and government programs aimed at reducing the prevalence of sexually transmitted infections are driving demand for herpes marker testing. Governments and global health organizations are investing in STI prevention and control programs, which include expanding access to diagnostic testing for herpes and other infections. These initiatives, combined with greater public awareness and technological advancements, are expected to drive steady growth in the herpes marker testing market in the coming years, ensuring that more individuals can access accurate diagnostics and effective care.
SCOPE OF STUDY:The report analyzes the Herpes Marker Testing market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Test Type (Antibody / Antigen-Based Kits, Nucleic Acid Amplification-Based Kits, Viral Culture Test); End-Use (Diagnostic Centers, Hospitals, Clinics, Academic & Research Institutes)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
SELECT PLAYERS -
- Abbott Laboratories
- Abcam Ltd.
- bioMerieux SA
- Bio-Rad Laboratories, Inc.
- DiaSorin SpA
- F. Hoffmann-La Roche AG
- Hologic, Inc.
- Merck KgaA
- Meridian Bioscience, Inc.
- Norgen Biotek Corporation
- Qiagen NV
- QuidelOrtho Corporation
- Teco Diagnostics
- Thermo Fisher Scientific, Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
- Global Economic Update
- Herpes Marker Testing – Global Key Competitors Percentage Market Share in 2026 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Global Prevalence of Herpes Infections Propels Demand for Herpes Marker Testing
- Expansion of Diagnostic Testing in Sexual Health Clinics Fuels Market Growth
- Role of Herpes Marker Testing in Reducing Transmission Rates and Enhancing Public Health Efforts
- Expansion of Home-based and Self-testing Solutions Strengthens Business Case for Herpes Diagnostics
- Growth in Digital Health Platforms for Telemedicine Consultations Expands Addressable Market
- Challenges in Managing Social Stigma and Awareness of Herpes Infections Pose Barriers to Adoption
- Expansion of Testing in Prenatal Care and High-risk Populations Drives Market Demand
- Growth in Use of Multiplex Testing Panels for STDs Expands Market Opportunities
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Herpes Marker Testing Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
- TABLE 2: World Recent Past, Current & Future Analysis for Herpes Marker Testing by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 3: World Historic Review for Herpes Marker Testing by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 4: World 13-Year Perspective for Herpes Marker Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
- TABLE 5: World Recent Past, Current & Future Analysis for Viral Culture Test Kits Test by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 6: World Historic Review for Viral Culture Test Kits Test by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 7: World 13-Year Perspective for Viral Culture Test Kits Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- TABLE 8: World Recent Past, Current & Future Analysis for Nucleic Acid Amplification-based Kits Test by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 9: World Historic Review for Nucleic Acid Amplification-based Kits Test by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 10: World 13-Year Perspective for Nucleic Acid Amplification-based Kits Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- TABLE 11: World Recent Past, Current & Future Analysis for Antibody / Antigen-based Kits Test by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 12: World Historic Review for Antibody / Antigen-based Kits Test by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 13: World 13-Year Perspective for Antibody / Antigen-based Kits Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- TABLE 14: World Recent Past, Current & Future Analysis for HSV-1 Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 15: World Historic Review for HSV-1 Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 16: World 13-Year Perspective for HSV-1 Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- TABLE 17: World Recent Past, Current & Future Analysis for HSV-2 Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 18: World Historic Review for HSV-2 Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 19: World 13-Year Perspective for HSV-2 Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- TABLE 20: World Recent Past, Current & Future Analysis for HSV-1 / HSV-2 Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 21: World Historic Review for HSV-1 / HSV-2 Indication by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 22: World 13-Year Perspective for HSV-1 / HSV-2 Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- TABLE 23: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 24: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 25: World 13-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- TABLE 26: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 27: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 28: World 13-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- TABLE 29: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 30: World Historic Review for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 31: World 13-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- TABLE 32: World Recent Past, Current & Future Analysis for Homecare Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 33: World Historic Review for Homecare Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 34: World 13-Year Perspective for Homecare Settings End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- TABLE 35: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 36: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 37: World 13-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
- III. MARKET ANALYSIS
- UNITED STATES
- Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
- TABLE 38: USA Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 39: USA Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 40: USA 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 41: USA Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 42: USA Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 43: USA 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 44: USA Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 45: USA Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 46: USA 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- CANADA
- TABLE 47: Canada Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 48: Canada Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 49: Canada 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 50: Canada Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 51: Canada Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 52: Canada 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 53: Canada Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 54: Canada Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 55: Canada 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- JAPAN
- Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
- TABLE 56: Japan Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 57: Japan Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 58: Japan 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 59: Japan Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 60: Japan Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 61: Japan 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 62: Japan Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 63: Japan Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 64: Japan 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- CHINA
- Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
- TABLE 65: China Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 66: China Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 67: China 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 68: China Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 69: China Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 70: China 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 71: China Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 72: China Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 73: China 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- EUROPE
- Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
- TABLE 74: Europe Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 75: Europe Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 76: Europe 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 77: Europe Recent Past, Current & Future Analysis for Herpes Marker Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 78: Europe Historic Review for Herpes Marker Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 79: Europe 13-Year Perspective for Herpes Marker Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
- TABLE 80: Europe Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 81: Europe Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 82: Europe 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 83: Europe Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 84: Europe Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 85: Europe 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- FRANCE
- Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
- TABLE 86: France Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 87: France Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 88: France 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 89: France Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 90: France Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 91: France 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 92: France Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 93: France Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 94: France 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- GERMANY
- Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
- TABLE 95: Germany Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 96: Germany Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 97: Germany 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 98: Germany Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 99: Germany Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 100: Germany 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 101: Germany Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 102: Germany Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 103: Germany 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- ITALY
- TABLE 104: Italy Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 105: Italy Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 106: Italy 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 107: Italy Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 108: Italy Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 109: Italy 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 110: Italy Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 111: Italy Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 112: Italy 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- UNITED KINGDOM
- Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
- TABLE 113: UK Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 114: UK Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 115: UK 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 116: UK Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 117: UK Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 118: UK 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 119: UK Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 120: UK Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 121: UK 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- SPAIN
- TABLE 122: Spain Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 123: Spain Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 124: Spain 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 125: Spain Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 126: Spain Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 127: Spain 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 128: Spain Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 129: Spain Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 130: Spain 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- RUSSIA
- TABLE 131: Russia Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 132: Russia Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 133: Russia 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 134: Russia Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 135: Russia Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 136: Russia 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 137: Russia Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 138: Russia Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 139: Russia 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- REST OF EUROPE
- TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 141: Rest of Europe Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 142: Rest of Europe 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 144: Rest of Europe Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 145: Rest of Europe 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 147: Rest of Europe Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 148: Rest of Europe 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- AUSTRALIA
- Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
- INDIA
- Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
- SOUTH KOREA
- REST OF ASIA-PACIFIC
- LATIN AMERICA
- Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
- TABLE 149: Latin America Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 150: Latin America Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 151: Latin America 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 152: Latin America Recent Past, Current & Future Analysis for Herpes Marker Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 153: Latin America Historic Review for Herpes Marker Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 154: Latin America 13-Year Perspective for Herpes Marker Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
- TABLE 155: Latin America Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 156: Latin America Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 157: Latin America 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 158: Latin America Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 159: Latin America Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 160: Latin America 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- ARGENTINA
- TABLE 161: Argentina Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 162: Argentina Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 163: Argentina 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 164: Argentina Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 165: Argentina Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 166: Argentina 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 167: Argentina Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 168: Argentina Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 169: Argentina 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- BRAZIL
- TABLE 170: Brazil Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 171: Brazil Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 172: Brazil 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 173: Brazil Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 174: Brazil Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 175: Brazil 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 176: Brazil Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 177: Brazil Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 178: Brazil 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- MEXICO
- TABLE 179: Mexico Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 180: Mexico Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 181: Mexico 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 182: Mexico Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 183: Mexico Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 184: Mexico 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 185: Mexico Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 186: Mexico Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 187: Mexico 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- REST OF LATIN AMERICA
- TABLE 188: Rest of Latin America Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 189: Rest of Latin America Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 190: Rest of Latin America 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 191: Rest of Latin America Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 192: Rest of Latin America Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 193: Rest of Latin America 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 194: Rest of Latin America Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 195: Rest of Latin America Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 196: Rest of Latin America 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- MIDDLE EAST
- Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
- TABLE 197: Middle East Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 198: Middle East Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 199: Middle East 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 200: Middle East Recent Past, Current & Future Analysis for Herpes Marker Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
- TABLE 201: Middle East Historic Review for Herpes Marker Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 202: Middle East 13-Year Perspective for Herpes Marker Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
- TABLE 203: Middle East Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 204: Middle East Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 205: Middle East 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 206: Middle East Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 207: Middle East Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 208: Middle East 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- IRAN
- TABLE 209: Iran Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 210: Iran Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 211: Iran 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 212: Iran Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 213: Iran Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 214: Iran 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 215: Iran Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 216: Iran Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 217: Iran 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- ISRAEL
- TABLE 218: Israel Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 219: Israel Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 220: Israel 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 221: Israel Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 222: Israel Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 223: Israel 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 224: Israel Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 225: Israel Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 226: Israel 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- SAUDI ARABIA
- TABLE 227: Saudi Arabia Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 228: Saudi Arabia Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 229: Saudi Arabia 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 230: Saudi Arabia Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 231: Saudi Arabia Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 232: Saudi Arabia 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 233: Saudi Arabia Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 234: Saudi Arabia Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 235: Saudi Arabia 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- UNITED ARAB EMIRATES
- TABLE 236: UAE Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 237: UAE Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 238: UAE 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 239: UAE Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 240: UAE Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 241: UAE 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 242: UAE Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 243: UAE Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 244: UAE 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- REST OF MIDDLE EAST
- TABLE 245: Rest of Middle East Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 246: Rest of Middle East Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 247: Rest of Middle East 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 248: Rest of Middle East Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 249: Rest of Middle East Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 250: Rest of Middle East 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 251: Rest of Middle East Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 252: Rest of Middle East Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 253: Rest of Middle East 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- AFRICA
- Herpes Marker Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
- TABLE 254: Africa Recent Past, Current & Future Analysis for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 255: Africa Historic Review for Herpes Marker Testing by End-Use - Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 256: Africa 13-Year Perspective for Herpes Marker Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2020, 2026 & 2032
- TABLE 257: Africa Recent Past, Current & Future Analysis for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 258: Africa Historic Review for Herpes Marker Testing by Test - Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 259: Africa 13-Year Perspective for Herpes Marker Testing by Test - Percentage Breakdown of Value Sales for Viral Culture Test Kits Test, Nucleic Acid Amplification-based Kits Test and Antibody / Antigen-based Kits Test for the Years 2020, 2026 & 2032
- TABLE 260: Africa Recent Past, Current & Future Analysis for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
- TABLE 261: Africa Historic Review for Herpes Marker Testing by Indication - HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
- TABLE 262: Africa 13-Year Perspective for Herpes Marker Testing by Indication - Percentage Breakdown of Value Sales for HSV-1 Indication, HSV-2 Indication and HSV-1 / HSV-2 Indication for the Years 2020, 2026 & 2032
- IV. COMPETITION
Pricing
Currency Rates


